JAK3 and B-cell chronic lymphocytic leukemia: We further employed Janus protein tyrosine kinase 1 (JAK1), JAK2, and JAK3 specific inhibitors to examine whether JAK signaling is involved in GIFT4-triggered STAT5 hyper phosphorylation in CLL cells.